Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.42 |
| ▸ | PGR | P06401 | 10/20 | 0.42 |
| ▸ | AR | P10275 | 10/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12397541 | 0.89 | NR3C1 (0.43) | NR3C1NR3C2PGRARPLA2G7 | |
| SCHEMBL1423391 | 0.88 | NR3C1 (0.46) | NR3C1NR3C2PGRARPLA2G7 | |
| SCHEMBL2161713 | 0.86 | NR3C1 (0.44) | NR3C1NR3C2PGRARPLA2G7 | |
| SCHEMBL2161725 | 0.86 | ALDH1A1 (0.34) | SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL7950082 | 0.85 | NR3C1 (0.42) | NR3C1NR3C2PGRARPLA2G7 | |
| SCHEMBL1422961 | 0.84 | NR3C1 (0.42) | NR3C1NR3C2PGRARPLA2G7 | |
| SCHEMBL1422696 | 0.84 | NR3C1 (0.42) | NR3C1NR3C2PGRARPLA2G7 | |
| SCHEMBL1422988 | 0.84 | NR3C1 (0.44) | NR3C1NR3C2PGRARPLA2G7 | |
| SCHEMBL1350173 | 0.83 | HDAC3 (0.31) | SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL1422784 | 0.81 | NR3C1 (0.42) | NR3C1NR3C2PGRARPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183928-A1 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183928-A1 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-28 | — | — | US | disclosed |
| WO-2009156091-A1 | 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183928-A1 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof | HTR3C, HTR3A, ADRB3 | NR3C1 2099/4885NR3C2 735/4885PGR 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.